🔴 High ImpactPharma
Suven Life Sciences reports positive Phase-2b trial results for Ropanicant
Suven Life Sciences reports positive Phase-2b trial results for Ropanicant. Company announced positive topline results from its Phase-2b proof-of-concept trial of Ropanicant in Major Depressive Disorder. The drug candidate showed statistically significant improvement over placebo with p-value <0.05. This success may accelerate development plans and boost investor confidence in the pipeline.
📊 STOCKS: SUVENLIFE | 🏢 SECTOR: Pharma | #HIGHIMPACT #ClinicalTrial
#ClinicalTrial#Pharma#Ropanicant#Depression
Stocks mentioned
⚠️ This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.
Trade smarter on NSE
Live option chains, FII flows, PCR, AI analysis — for NIFTY, BANKNIFTY & 200+ F&O stocks.
Start for ₹1 →